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Abstract 
Purpose: To determine through a literature review, the current status of patients’ involvement in 
adverse drug reactions (ADRs) reporting. 
Methods: Eighteen (18) studies which were published within the period from 2010 to 2016 were 
reviewed. The studies were extracted from seven databases, viz, Google Scholars, Medline, Academic 
Search Complete “EBSCO”, Health and Medical Complete ProQuest, Science Direct- Elsevier, 
SCOPUS and Wiley Online Library. 
Results: The review revealed that although the reports by patients were of good quality, the patients’ 
awareness of, and attitude towards, ADR reporting were generally poor. 
Conclusion: The results of this review suggest the need for patients’ enlightenment on ADRs reporting. 
Information on how to improve ADRs reporting is provided. 
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Patient-centeredness is defined as “health care 
that establishes a partnership among 
practitioners, patients, and their families (when 
appropriate) to ensure that decisions respect 
patients' wants, needs, and preferences, and that 
patients have the education and support they 
need to make decisions and participate in their 
own care” [1].  
 
Recently, patients’ perspectives were 
incorporated into pharmacovigilance (PV) 
activities such as ADR reporting, signal detection 
and evaluation, risk management, medication 
error assessment, benefit–risk assessment and 
risk communication [2]. This review focuses on 
the participation of patients in reporting ADRs.  
 
Adverse drug reactions (ADRs) are global 
problems in both developing and developed 
countries, where they contribute to significant 
morbidity and mortality [3-6].  A meta- analysis 
published in 1998 ranked ADRs between the 
fourth and the sixth leading causes of death in 
the US [7]. The main aim of documenting ADRs 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2018 The authors.. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
Saleh et al 
Trop J Pharm Res, January 2018; 17(1): 180 
 
is to prevent future injuries to patients [8]. 
 
The importance of patients ADRs reporting:  
New,   unexpected   and   rare   ADRs  are  often  
discovered when drugs are used in larger or in a 
different population than studied during initial 
clinical trials which are conducted in a controlled 
environment in a limited number of patients and 
with specific, notably short duration. Since the 
early 1960s, spontaneous reporting has been the 
main method of information on adverse reactions 
while healthcare professionals (HCPs) provide 
the information. However, underreporting has 
been a major drawback in this information. 
Therefore, reports from patients/consumers will 
be an extra source of information which may help 
in reducing the limitation imposed by 
underreporting [3,8-11]. A study conducted in the 
UK, which evaluated the effect of patients’ 
reporting on signal generation, demonstrated that 
combining patients’ reports with HCPs reports 
resulted in generation of 47 new signals for 
serious ADRs [12]. 
 
Furthermore, consumer reporting provides first-
hand information about their experience with 
drugs which helps in early detection of ADRs, 
resulting in identification of more and unknown 
ADRs, especially with over-the-counter (OTC) 
and herbal drugs [13,14]. Some studies showed 
that patients identify and report ADRs quicker 
and earlier than HCPs do, and also provide more 
information related to their quality of life [15,16]. 
In addition, direct patients’ reporting promotes 
patients’ rights and improves their involvement in 
their health management [10]. 
 
Avenues for patients reporting 
 
The World Health Organization (WHO) stated 
that reporting routes should be made readily 
accessible and cheap. Patients/ consumers may 
submit their reports by telephone, or through fax, 
e-mail, e-forms and paper forms which can be 
submitted in a pre-paid post. Paper forms should 
be available at local pharmacies, healthcare 
facilities or offices or in magazines produced by 
patients’ organizations [9]. 
 
How to improve patients’ engagement in 
ADRs reporting 
 
Article 102, directive 2010/84/EU of the 
European Parliament, and of the Council of 15 
December 2010 as amended regarding 
pharmacovigilance in Directive 2001/83/EC on 
the Community code relating to medicinal 
products for human use, stated “The member 
states shall take all appropriate measures to 
encourage patients, doctors, pharmacists and 
other healthcare professionals to report 
suspected adverse reactions to the national 
competent authority; for these tasks, 
organizations representing consumers, patients 
and healthcare professionals may be involved as 
appropriate” [17]. Therefore, patients reporting 
can be encouraged by: 
 
1- Helping patients to share their experiences. 
It is important to increase their knowledge 
and awareness, and educate them about 
the importance of their participation through 
leaflets, posters, advertising through radio 
or television, and the use of the internet 
through websites or social media [9].  
2- Involving HCPs to increase their patients’ 
awareness [13].  
3- Sending electronic reminders via emails or 
telephone call to patients/customers to 
encourage them to report [13].  
4- Ensuring that the means of reporting are 
well known and easily accessible [9].  
5- Ensuring that reporting forms contain clear 
instructions [9].  
6- Acknowledging the receipt of reports by 
phone calls, letters or emails [9].  
7- Providing the public a feedback by statistics 
published on public websites or in public 
newsletters [9].  
 
An Italian study has presented the impact of a 
regional program in promoting patients reporting 
where 211 pharmacists working in 118 
community pharmacies were involved [14]. Each 
pharmacist was asked to select, during the study 
period, about 250 customers who had received 
at least one drug, and to present the 
spontaneous reporting form to those who had 
experienced a suspected ADR.  
 
In a 4-month period, 52,495 customers were 
interviewed by the pharmacists and 4,949 of 
them made reference to a suspected ADR. The 
PV Centre of the Veneto region received 2,311 
ADR reporting forms related to the study from 
customers. This study reinforces the need for 
creation of a partnership between practitioners 
and patients, and the impact of encouragement 
on patients’ reporting [14].  
 
The general aim of this review was to determine 
the status of patient’s engagement in ADR 
reporting. The specific objectives were to identify 
patients’ knowledge, attitude, and experience 
with ADRs reporting, as well as methods of 
patients’ reporting, quality of patients’ reports, 
factors that encourage patients to report, barriers 
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to patients’ reporting and factors that can help 






Google Scholar, Medline, Academic Search 
Complete “EBSCO”, Health and Medical 
Complete ProQuest, Science Direct- Elsevier, 
SCOPUS and Wiley Online Library were used to 
identify relevant publications related to patients’ 
participation in ADRs reporting. The keywords 
and keyword combinations used were “patients 
and patient participation”; “ADR reporting”, and 
“drug-related side effects and adverse 
reactions”’. The MeSH terms for Medline search 
were: "Patients"[Mesh] or "Consumer 
participation"[Mesh]) and “Drug-related side 
effects and adverse reactions" [Mesh] or 
"Adverse drug reaction reporting systems" 
[Mesh]) and "2010/01/01"(PDAT): 
"2016/12/31"[PDAT]) and "humans" [MeSH 
Terms]) and ("2010/01/01"[PDAT]: 
"2016/12/31"[PDAT]). 
 
Review of the selected articles 
 
All the articles found were reviewed in the 
different bibliography databases, first according 
to title, then according to the information 
provided by the abstracts, and then according to 
the full text. At each step, articles were either 
retained for analysis, or excluded (Error! 
Reference source not found.). For each 
selected full paper, the inclusion criteria were: 
English studies published from 2010 to 2016, 
and papers with clear objectives, for example 
studies aimed at assessing patients’ 
experiences, analysis of patients’ reports, and 
any objective compatible with the stated 




Description of articles included 
 
A total of 18 articles met the inclusion criteria. 
Three studies investigated the situation of 
patients reporting in multiple countries (17, 50 
and 11 countries). The highest number of studies 
(8 studies) were carried out in the UK, followed 
by the Netherland (4 studies, Figure 2). 
 
Summary of results according to study 
technique 
 
Majority of articles (11) were descriptive studies 
using self-administered questionnaires, 
interviews, and telephone interviews. Six (6) 
studies were retrospective analysis of patients’ 
reports, while one investigation was a 




Subjects: Patients, consumers, and the general 
population 
 
A study published in 2015 was conducted in 
Portugal to investigate knowledge and attitude of 
948 consumers from community pharmacy about 
ADRs reporting. It revealed that 44.1 % of the 
consumers never heard about the national PV 




Figure 1: Publication selection process 
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Figure 2: Distribution of reviewed articles according to countries 
 
the possibility of reporting to HCPs. More than 
half (57.6 %) believed that they had already 
suffered from an ADR although only one 
consumer previously reported directly to the 
national PV system. Although 51 % of the 
consumers believed that they would benefit from 
reporting ADRs, only 27.8 % of them believed 
they should be responsible for reporting. When 
asked what they would do when they have 
ADRs, the percentages that stated that they 
would visit their GP, talk to their pharmacy, and 
report spontaneously were 39.9, 33.7 %, and 
32.2 %, respectively) [18]. 
 
Two studies conducted in Thailand, published in 
2015 and 2014 investigated Thai patients’ 
experience with ADRs reporting [22]. The first 
study indicated that out of 257 patients who 
experienced suspected ADRs, more than half 
(59.1%) reported only one symptom as ADR, 
while 40.9% reported more than one symptom. 
 
After stopping the medicine, 60.1 % reported that 
the symptoms disappeared, and 36.9 % reported 
that the symptoms were reduced. More than 56 
% of the respondents felt high certainty about the 
suspected ADR [22]. The second study 
interviewed 100 patients whereby 51 % of them 
reported between one and five symptoms 
suspected as ADRs, while the rest reported more 
than 5 symptoms. About 56% of the reported 
symptoms were assessed to be accurate.  A 
significant portion of the respondents (74%) 
claimed a relationship between duration of drug 
usage and ADRs, while 25% of them said that 
the symptoms disappeared or decreased on 
dechallenge [23]. 
 
A study conducted in Sweden to estimate one- 
month prevalence of self-reported ADRs among 
7,099 adults from the general population 
revealed that 19.4% reported at least one ADE. 
About 32.9% of the 2,578 reported ADEs were 
ADRs; 0.8% were drug intoxications, 6.7 were 
drug dependencies, while 30.7% were 
morbidities due to drug-related untreated 
indications [24].  
 
In one UK-based study to investigate how 
reporters to YSC identified ADRs, 16.7% of 
1,362 respondents indicated that the symptoms 
were not present before the drug was 
administered, while 27.4% said that the 
symptoms manifested soon after starting the 
drug. Regarding their source of information, 
HCPs, patient information leaflet, and the internet 
constituted 15.9%, 8.4%, and 4.9%, respectively 
[25,26].  
 
Subjects: National regulatory authorities/ 
organizations 
 
Three studies [27-29] assessed the situation of 
patients reporting in different countries through 
self-administered questionnaires, interviews or 
phone calls to the national regulatory authorities 
in different countries. Table 1 shows the 
distribution of countries covered in these studies 
according to the year of country’s acceptance of 
patients’ reporting, and the methods of reporting. 
The results show that 44 countries allowed 
patients, relatives, and patients’ associations to 
directly report ADRs to their National Health 
Competent Authorities (NCA). The first country to 
allow patients’ reporting was Australia in 1964, 
followed one year later by New Zealand and 
Canada, and then USA in 1969. In the 1990s, 
three countries (Colombia, Hungary, and  
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Table 1: Year of acceptance of patients' reports, and methods of reporting in 52 countries 
 
S/no.  Country Year patient 
reporting 
started 
Method of patients’ reporting 
Paper forms Electronic 
forms 
Phone 
1 Algeria 2012 or 2013 Yes  Yes NI 
2 Argentina 2012 or 2013 Yes  Yes NI 
3 Australia  1964  Yes  Yes  Yes  
4 Austria 2012 or 2013 Yes Yes NI 
5 Belgium 2012 or 2013 Yes  Yes NI 
6 Brazil 2000s Yes  Yes NI 
7 Bulgaria 2012 or 2013 Yes  No  NI 
8 Canada 1965 Yes  Yes Yes  
9 China 2012 or 2013 Yes  Yes NI 
10 Colombia 1990s Yes  No  NI 
11 Croatia 2000s Yes  Yes NI 
12 Cuba No patient reporting NA NA NA 
13 Cyprus No patient reporting NA NA NA 
14 Czech Republic 2000s Yes  Yes NI 
15 Denmark 2000s No   Yes No  
16 Estonia 2012 or 2013 Yes  Yes NI 
17 Finland 2012 or 2013 Yes  No  NI 
18 France 2012 or 2013 Yes  No  NI 
19 Germany 2012 or 2013 Yes  Yes NI 
20 Greece 2012 or 2013 Yes  Yes NI 
21 Hungary 1990s Yes  Yes NI 
22 India 2012 or 2013 Yes  No Yes  
23 Ireland 2012 or 2013 Yes  Yes NI 
24 Israel 2012 or 2013 NI NI NI 
25 Italy 2012 or 2013 Yes  No  NI 
26 Japan 2012 or 2013 Yes  Yes NI 
27 Kenya 2012 or 2013 Yes  Yes NI 
28 Latvia 2012 or 2013 Yes  Yes NI 
29 Lithuania 2012 or 2013 Yes  Yes NI 
30 Luxembourg 2012 or 2013 Yes  Yes  NI 
31 Malta 2000s Yes  Yes NI 
32 Malaysia  NI Yes  No  Yes  
33 Mexico 2012 or 2013 Yes  Yes NI 
34 Morocco 2000s Yes  Yes NI 
35 The Netherland 2000s No   Yes No  
36 New Zealand 1965 Yes  Yes Yes  
37 Nigeria 2000s No  No Text 
message 
38 Norway 2012 or 2013 No   Yes No  
39 Peru No patient reporting NA NA NA 
40 Philippines  NI Yes  No  Yes  
41 Poland 2012 or 2013 Yes  Yes NI 
42 Portugal 2012 Yes  Yes NI 
43 Romania No patient reporting NA NA NA 
44 Russia No patient reporting NA NA NA 
45 Slovakia 2012 or 2013 Yes  Yes NI 
46 Slovenia 1990s Yes  Yes NI 
47 South Africa No patient reporting NA NA NA 
48 Spain 2012 or 2013 Yes  Yes NI 
49 Sweden 2000s Yes  Yes NI 
50 Switzerland 2000s Yes  Yes No  
51 UK 2000s Yes  Yes Yes  
52 USA 1969 Yes  Yes Yes  
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Slovenia), and in the 2000s, twelve countries 
(Brazil, Croatia, Czech Republic, Denmark, Italy, 
Malta, Morocco, the Netherlands, Nigeria, 
Sweden Switzerland, and the UK) started 
establishing patient reporting, while the 
remaining countries started in 2012 or 2013. 
Regarding the reporting methods, 33 countries 
used online and paper reporting, 5 countries 
used paper forms only, 3 countries used online 
forms only, and one country used text messages. 
Furthermore, three countries (Germany, New 
Zealand, and Kenya) currently offer patients the 
opportunity to report through downloaded application 
for mobile devices. 
 
Retrospective analysis of patients’ reports 
 
A study in India which evaluated 200 patients’ 
reports revealed that more than half of the 
patients (54.3%) provided their contact 
information, and 80% of them described the 
ADRs, but details about concomitant drugs were 
missing [30]. The study suggested that in order 
to avoid missing out information, the required 
field should be highlighted or described as 
mandatory, and that the public should be 
educated to improve the quality of their reports 
[30]. In a UK-based study published in two 
articles, the first article dwelt on the relative 
contribution of patients in ADRs reporting by 
analysis of 5,180 patients’ ADRs reports and 
20,949 reports from HCPs which were submitted 
to YSC [31]. It revealed that 10.6% of ADRs were 
reported by both patients and HCPs. 
Furthermore, the combination of data from 
patients and HCPs reports identified an extra 508 
signal of disproportionate reports (SDRs) that 
were not identified by analysis of the patient or 
HCPs datasets alone [31]. The second article 
which compared the characteristics of patients’ 
and HCPs’ reports,  revealed that the most 
frequent method used to report an ADR was the 
paper YC for both reporter groups (61.1% and 62 
%, respectively). The Internet was the next most 
frequently used method (13.6% and 8.7%, 
respectively), followed by the telephone (2.7% 
and 0.02%, respectively). Furthermore, patients 
tended to report a significantly higher number of 
suspected ADRs per YC report than HCPs, with 
median values of 3 (2–5) and 2 (1–3), 
respectively [32]. In another study in the UK, in 
which 230 reports were analyzed in order to 
understand how reporters to YSC identified the 
ADRs, it was shown that 74.8% of the reports 
included at least one aspect of association of the 
drug and the symptom, 61.3% stated that 
symptoms began after starting the drug, while 
26.1% indicated that the symptoms reduced on 
dose reduction or complete withdrawal [25]. A 
study was conducted in France to investigate the 
quality of 1,006 patients’ reports submitted to the 
French PV system [33]. These reports were 
classified as serious, medically serious, and non-
serious ADRs (2.3%, 6.2%, and 91.5%, 
respectively). Moreover, 91.3% of the serious 
ADRs were ranked as possible but none of the 
patients’ reports were classified as likely.No 
differences were found in unlabeled, serious 
ADRs between the patients’ reports and HCPs 
reports (56.5% and 56.7%, respectively) [33]. A 
study in Sweden analyzed 442 consumers’ 
reports regarding antidepressant drugs. It 
revealed that 878 out of 2,392 reported ADRs 
were psychiatric in nature [34]. Approximately, 
one-third of psychiatric ADRs were reported by 
patients within the age group of 30-39 years, 
while 23.9% were reported by patients in the 15-
29 years age group [34]. 
 
Prospective observational study  
 
A Canada-based study aimed at assessing 
patients’ contributions in ADRs reporting through 
telephone follow-up entailed prospective 
observation of 258 patients who were discharged 
from the emergency department (ED) [35]. It 
showed that one-quarter (25.2%) of the patients 
reported symptoms they believed were ADRs 
from ED discharge medications; 20.9% reported 
symptoms that met the researchers’ definition of 
a patient-reported ADRs, while 24% of the 
patients had unplanned visits to ED, 5% of which 
were felt to be related to an ADRs [35]. 
 
Why patients did report or failed to report 
 
In three studies [18,19,21], patients stated 
factors that can encourage or discourage them 
from reporting. Most of the patients stated they 
would report if the ADRs were serious, and that 
they liked to share their experiences. However, 
they said they would not report if the drug effect 
was not serious, expected or known (Table 2). 
 
Patients’ suggestions for improvement 
 
In one study, patients gave some suggestions for 
improving their contributions to reporting [19]. 
Most of them agreed on the importance of 
publicity and promotion of the reporting scheme 




The involvement of patients in their health care 
management is one of their basis rights. Patients’ 
rights should be the prime concern of any health 
care system, and one of patient-centered 
pharmacovigilance activities is the engagement 
of patients in reporting of ADRs. 
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-Greater publicity and promotion of 
the scheme by HCPs, and wider 
availability and accessibility of the 
reporting forms. (n=143).  
-Suggestions for improvement to the 
forms:   
 More space. (n=31). 
 Simplifying questions. (n =15). 
 Simpler language. (n= 3). 
 
The known problem of underreporting of ADRs 
from HCPs emphasizes the importance of 
consumers’ reporting as new and extra source of 
information. Thus, suspected ADRs can be 
detected and identified early, thereby decreasing 
their cost and burden on public health. Based on 
the various articles reviewed, it is clear that 
patients have inadequate knowledge and attitude 
regarding ADRs reporting and drug safety. 
 
Where they were unaware of the existence of PV 
system, 44.1% of patients believed that drugs 
prescribed physicians were completely safe, and 
that physicians were responsible for any side 
effects that occurred.  Patients believed that they 
would benefit from reporting (51%- 93.7%) and 
stated that they felt responsible for reporting 
(27.8 - 92.5%).     Regarding their experiences, 
some patients (19.4% - 59%) stated that they 
reported between 1 to 5 symptom, and most of 
them (93.6%) said the report form was easy to 
complete. Patients (16.7- 74%) identified the 
ADRs by setting a relationship between time of 
starting the drug and the reported symptoms, 
and 77% stopped the treatment. In addition, 32.2 
– 92.5 % stated that if they experienced an ADR 
in future, they would report again; 39.9 % said 
they would visit their GP, while 33.7% stated that 
they would talk to their pharmacists.  Most 
patients stated that they expected to have 
feedback and they would like to have feedback. 
Most of countries (33 countries) used papers and 
an online form to receive patients’ reports; 5 
countries used paper forms only, while 3 
countries used electronic forms only.  
Notwithstanding the current era of technology, 
only one country used text messages, while 3 
countries used application for mobile devices. 
The quality of patients’ reports was relatively 
good, and there were no major qualitative 
differences between patients’ reports and HCPs’ 
reports. Patients described the ADRs and they 
indicated at least one aspect associated with the 
drug and the symptoms. Furthermore, patients 
reported a significantly higher number of 
suspected ADRs when compared to HCPs’ 
reports; most of reported serious events were 
ranked as possible (91.3%), and their reports 
helped in identifying extra signals. However, 
there were some missing details e.g. information 
on concomitant drugs. The reviewed articles 
indicated that some patients did not report either 
because they were discouraged by their GP, or 
HCPs refused to make a report on their behalf, or 
their GP was unaware of direct patients reporting 
[19]. Since HCPs are considered the prime 
source of information for patients, it is necessary 
to improve their awareness and attitude 
regarding direct patients reporting, and to 
develop a culture of partnership with their 
patients. In addition, HCPs should be 
encouraged to involve their patients through 
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incentives and enlightenment, so as to decrease 
their workload. One of the reviewed articles 
indicated that patients reported ADRs because 
their pharmacist told them to do that [19]. 
Therefore, HCPs should encourage their patients 
to report, and educate their patients on how to 
report and how to identify the ADRs. This review 
has established that patients’/ consumers’ 
knowledge of ADRs, and their attitude towards 
them are inadequate. Therefore, there is need to 
increase their awareness through educational 
campaign, posters and television advertisements 
to ensure that patients have enough time during 
their visits to get enough information from their 
HCPs. The current advancements in information 
technology should be exploited by way of 
sending text messages, phone calls, and 
reminder emails to patients to encourage them to 
speak up, and also by establishing mobile 
applications as means of reporting. Furthermore, 
PV centers may establish their own Twitter and 
Facebook accounts to spread the culture of 
reporting to the community. There is also the 
need to establish projects for data mining of 
safety information published by the community 
through the social media.  The means of 
reporting should be well known, easily 
accessible, have enough space and be 
presented in a simple language.  Lastly, 
information from patients’ reports should be 
made available to them through PV centers’ 




This review has provided data on patients’ KAP, 
quality of patients’ ADRs reporting, and direct 
patients reporting status in many countries. It 
showed poor knowledge and inadequate attitude 
of patients about ADRs reporting, and provided 
information about how to improve ADRs 
reporting by patients. In addition, it has 
emphasized the need for patients’ education and 
training of health care professionals on the need 
for building partnership with patients.   
 
Strengths and limitations of this review 
 
The strength of this review lies in the fact that it 
has gathered information about patients’ KAP, 
direct patients’ reporting status in many 
countries, and the quality of patients’ reports in 
one review, through accessing full text of all 
articles involving relevant studies in the last six 
years. The limitations are that the reviewed 
descriptive studies used self-administered 
questionnaire, which often is fraught with low 
response rates and information bias, especially if 
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